<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37265384</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Parkinsonism as the presenting manifestation of lupus: A case-based review.</ArticleTitle><Pagination><StartPage>1001</StartPage><EndPage>1007</EndPage><MedlinePgn>1001-1007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231181636</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Neuropsychiatric manifestations in systemic lupus erythematosus (SLE) occur in about half of the patients; however, movement disorders like Parkinsonism are rare. We describe a case of SLE who presented solely with features of Parkinsonism.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="METHODS">50-year-old female presented with global slowing of movements and slowing of speech since 2&#xa0;months. On examination, she had mask-like facies with a faint malar rash sparing the nasolabial folds, hard palate ulcer, cog-wheel rigidity, and proximal muscle weakness. Lab evaluation revealed lymphopenia, high ESR, elevated lactate dehydrogenase, creatinine phosphokinase, AST, and ALT levels. She had high anti-dsDNA levels with low complements. Urinalysis showed proteinuria and hematuria. ANA was positive at a titer of 1:320, and she had positive anti-ribosomal-P antibody. She had severe flare with a SLEDAI of 33. She was treated with pulse IV methylprednisolone followed by cyclophosphamide (NIH protocol). At 4&#xa0;weeks follow-up, she had dramatic improvement in her Parkinsonian symptoms and her proximal muscle weakness.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The prevalence of movement disorders in cases of neuropsychiatric SLE is very low at 0.7%, with chorea being most frequent and Parkinsonism rare. The pathogenesis is multifactorial including anti-dopaminergic antibodies or associated anti-phospholipids causing microvascular thrombosis or vasculitis of the thalamostriatal arteries or disease activity itself. As in our case, immunosuppression and optimal treatment of active lupus reverts symptoms in most cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A high index of suspicion needs to be exercised in cases of SLE presenting with Parkinsonism as adequate immunosuppression translates to near-complete recovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mv</LastName><ForeName>Prakashini</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation><Identifier Source="RINGGOLD">90946</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maikap</LastName><ForeName>Debashis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation><Identifier Source="RINGGOLD">90946</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padhan</LastName><ForeName>Prasanta</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation><Identifier Source="RINGGOLD">90946</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000721270">malar rash</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinsonism</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">neuropsychiatric lupus</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>13</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37265384</ArticleId><ArticleId IdType="doi">10.1177/09612033231181636</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>